NGS‐MRD negativity in post‐HSCT ALL spares unnecessary therapeutic interventions triggered by borderline qPCR results without an increase in relapse risk

Abstract Monitoring of minimal residual disease (MRD) after hematopoietic stem cell transplantation (HSCT) in patients with acute lymphoblastic leukemia (ALL) is vital for timely therapeutic intervention planning. However, interpreting low‐positive results from the current standard method, quantitat...

Full description

Bibliographic Details

Published in:	HemaSphere
Main Authors:	Krystof Seferna, Michael Svaton, Andrea Rennerova, Aneta Skotnicova, Leona Reznickova, Tatana Valova, Petr Sedlacek, Petr Riha, Renata Formankova, Petra Keslova, Lucie Sramkova, Jan Stary, Jan Zuna, Alexandra Kolenova, Cyril Salek, Jan Trka, Eva Fronkova
Format:	Article
Language:	English
Published:	Wiley 2025-04-01
Online Access:	https://doi.org/10.1002/hem3.70124